Fractionation and Profiling of Heterogeneous Circulating Tumor Cells Using a Hyperuniform- Structured Microchip
Fractionation and Profiling of Heterogeneous Circulating Tumor Cells Using a Hyperuniform- Structured Microchip
批准号:
10025872
负责人:
Wei Li
金额:
$55.31万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-08-07 至 2024-07-31
关键词:
AddressAdherenceAdhesionsAdhesivesAdoptedAffinityBloodBlood CellsBlood specimenCD44 geneCD47 geneCancer BiologyCell AdhesionCell CycleCell LineCell SeparationCell SizeCell SurvivalCellsCharacteristicsClinicalClinical OncologyCollaborationsCorrelation StudiesDevicesDiagnosticDisease modelEnsureFractionationGenomicsGoalsHealth SciencesHeterogeneityImmunofluorescence ImmunologicIn SituIndividualLNCaPLabelLaboratory ResearchLocationMalignant NeoplasmsMetastatic Neoplasm to the BoneMetastatic Neoplasm to the LiverMetastatic Neoplasm to the LungMethodsMicrofluidic MicrochipsMicroscopeMonitorMorphologic artifactsNeoplasm Circulating CellsNeoplasm MetastasisOpticsPC3 cell linePatternPhenotypePopulationPopulation HeterogeneityProcessProteomicsProtocols documentationPumpRecoveryReportingResearchResearch PersonnelResolutionSamplingSensitivity and SpecificityStructureSurfaceSyringesTACSTD1 geneTechnologyTimeTreatment EfficacyWorkYangassay developmentbasebiophysical propertiescancer cellcancer diagnosiscancer therapycell typeclinical applicationclinical caredensitydesigninnovationinsightmanufacturing processmicrochipmicrofluidic technologypreventsample fixationscreeningtooltumortumor progression
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Title: Fractionation and Profiling of Heterogeneous Circulating Tumor Cells Using a
Hyperuniform-structured Microchip
Project Summary/Abstract
Circulating tumor cells (CTCs) are highly heterogeneous, and specific CTC subpopulations, rather than the whole,
are responsible for cancer metastasis. Current CTC technologies simply isolate all CTCs in a blood sample
without resolving them into distinct subpopulations, preventing researchers from acquiring true insights into the
metastatic potential of CTCs. As a consequence, correlation between CTC heterogeneity and tumor progression
is largely unknown. In addition, existing CTC characterization methods often involve destructive fixation and
permeabilization protocols, which limit the potential for subsequent phenotypic analysis of CTCs and other
downstream applications. The goal of this proposal is to understand the metastatic potential of CTCs through
effective fractionation and profiling of CTC subpopulations. I propose to isolate, in-situ identify, and selectively
recover CTCs using a microchip with hyperuniform structure. Hyperuniformity (HU) is an emerging concept of a
packing pattern which contains local heterogeneity or randomness and global regularity or homogeneity. My
work, for the first time, will integrate the concept of hyperuniformity into affinity-based microfluidic devices for
CTC isolation. I hypothesize that due to the controlled differences in local flow patterns induced by the
hyperuniform structure, cell arrest in different locations on the microchip will require different adhesive strengths.
Further, this adhesive strength is anticipated to be related to the types and densities of surface markers on the
captured CTCs and therefore, their metastatic character. Specific aims include (1) Design and characterize HU
structured microchip for CTC capture and analyze flow pattern and adhesion force in the device; (2) Capture and
identify subpopulations of CTCs with variable expression of the surface marker using a HU microchip; and (3)
Explore several key factors for potential incorporation of the HU microchip platform into clinical oncology settings.
The HU microchip offers a simple and unique resolution for fractionation of CTCs, as its global homogeneity
provides equal possibility of CTC adherence; and local heterogeneity allows simultaneous differentiation of
subpopulations by analyzing adhesive strength required for individual CTCs. As a result, subpopulations of CTCs
can be identified using only their capture locations on the HU chip without requiring additional post-capture
immunofluorescence characterization. The most significant quantitative milestones are to achieve 80% accuracy
on statistical correlation on: 1) the locations on a HU chip with strength of cell-post interaction, 2) predictions of
location vs. cell type in a cancer cell mixture (PC3 and LNCaP), and 3) achieving 80% accuracy on identification
of released EMT and non-EMT cells from their locations on a HU microchip, validated by immunostaining. If
successfully developed, this HU microchip can be easily integrated into research laboratories to study
fundamental cancer biology related to CTC heterogeneity, as well as into clinical settings to profile CTC
subpopulations to assist cancer diagnosis, predict tumor progression, and monitor therapeutic efficacy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Developing a novel disease-targeted anti-angiogenic therapy for CNV
-
批准号:10726508
-
项目类别:
-
资助金额:$44.0万
-
财政年份:2023
-
负责人:Wei Li
-
依托单位:
Integrative genomic and functional genomic studies to connect variant to function for CAD GWAS loci
-
批准号:10639274
-
项目类别:
-
资助金额:$80.25万
-
财政年份:2023
-
负责人:Wei Li
-
依托单位:
IMAT-ITCR Collaboration: Develop deep learning-based methods to identify subtypes of circulating tumor cells from optical microscope images
-
批准号:10675886
-
项目类别:
-
资助金额:$7.19万
-
财政年份:2022
-
负责人:Wei Li
-
依托单位:
The Pathophysiological Role of Cerebellar Glia in Rett Syndrome
-
批准号:10183494
-
项目类别:
-
资助金额:$39.94万
-
财政年份:2021
-
负责人:Wei Li
-
依托单位:
The role and mechanism of necrosis in glioblastoma
-
批准号:10097263
-
项目类别:
-
资助金额:$39.35万
-
财政年份:2021
-
负责人:Wei Li
-
依托单位:
The role and mechanism of necrosis in glioblastoma
-
批准号:10330992
-
项目类别:
-
资助金额:$39.35万
-
财政年份:2021
-
负责人:Wei Li
-
依托单位:
The Pathophysiological Role of Cerebellar Glia in Rett Syndrome
-
批准号:10591567
-
项目类别:
-
资助金额:$36.49万
-
财政年份:2021
-
负责人:Wei Li
-
依托单位:
The role and mechanism of necrosis in glioblastoma
-
批准号:10553723
-
项目类别:
-
资助金额:$39.35万
-
财政年份:2021
-
负责人:Wei Li
-
依托单位:
The Pathophysiological Role of Cerebellar Glia in Rett Syndrome
-
批准号:10380144
-
项目类别:
-
资助金额:$36.49万
-
财政年份:2021
-
负责人:Wei Li
-
依托单位:
A new drug entity for combination therapy of diabetic retinopathy
-
批准号:10255782
-
项目类别:
-
资助金额:$25.66万
-
财政年份:2021
-
负责人:Wei Li
-
依托单位:
Regio- and Enantioselective Alkene Difunctionalizations for the Synthesis of Bioactive Molecules.
-
批准号:10046958
-
项目类别:
-
资助金额:$45.15万
-
财政年份:2020
-
负责人:Wei Li
-
依托单位:
Transfer: DNA Methylation Canyons in Human Cancers: Methods, Target Genes and Functional Consequences
-
批准号:10119943
-
项目类别:
-
资助金额:$57.42万
-
财政年份:2020
-
负责人:Wei Li
-
依托单位:
Transfer: DNA Methylation Canyons in Human Cancers: Methods, Target Genes and Functional Consequences
-
批准号:10543784
-
项目类别:
-
资助金额:$55.02万
-
财政年份:2020
-
负责人:Wei Li
-
依托单位:
Transfer: DNA Methylation Canyons in Human Cancers: Methods, Target Genes and Functional Consequences
-
批准号:10330018
-
项目类别:
-
资助金额:$55.02万
-
财政年份:2020
-
负责人:Wei Li
-
依托单位:
Anti-angiogenic gene therapy of ocular vascular diseases
-
批准号:9909566
-
项目类别:
-
资助金额:$22.5万
-
财政年份:2020
-
负责人:Wei Li
-
依托单位:
Computational and Experimental Modeling of Epigenetic DNA Methylation
-
批准号:10091784
-
项目类别:
-
资助金额:$36.77万
-
财政年份:2020
-
负责人:Wei Li
-
依托单位:
Impaired Astroglial Glutamate Signaling in Rett Syndrome
-
批准号:10116102
-
项目类别:
-
资助金额:$40.84万
-
财政年份:2020
-
负责人:Wei Li
-
依托单位:
Thymidine Phosphorylase: a Novel Target of Antiplatelet Therapy
-
批准号:10448031
-
项目类别:
-
资助金额:$44.4万
-
财政年份:2019
-
负责人:Wei Li
-
依托单位:
A selective angiogenesis blocker to treat retinopathy of prematurity
-
批准号:10580497
-
项目类别:
-
资助金额:$7.6万
-
财政年份:2019
-
负责人:Wei Li
-
依托单位:
Modeling Functional Elements using CRISPR Screening
-
批准号:10627916
-
项目类别:
-
资助金额:$44.63万
-
财政年份:2019
-
负责人:Wei Li
-
依托单位:
海外基金